Sequenom — JP Morgan Healthcare Conference 2015
26 slides from Sequenom's conference presentation, Jan 12, 2015
Slide 1: Interpreting the genome to improve your life
Interpreting the genome to improve your life Exhibit 99.1 JP Morgan Healthcare Conference January 12-15, 2015 Bill Welch, CEO
Slide 2: Forward-looking statements
Except for historical information, matters set forth in this presentation, including statements regarding Sequenom’s plans, potential, opportunities, financial or other expectations, projections, goals, objectives, milestones, strategies, market growth, timelines, product pipeline, clinical studies,
Slide 3: The core of Sequenom's culture: quality of science
The core of Sequenom’s culture is a single uncompromising principle… QUALITY OF SCIENCE CLINICAL FOCUS Reproductive health Women’s health Whole genome sequencing
Slide 4: Company Snapshot
Company Snapshot** 2014 Highlights Focused leader in Noninvasive Prenatal Testing (NIPT) $ Millions Revenue * Preliminary, unaudited. Cash burn excludes the proceeds and payments from the Illumina, ISIS, and CUHK transactions in 2014. ** Revenue and cash burn have been adjusted to remove discontinue
Slide 5: Sequenom and Illumina Settlement
Sequenom and Illumina Settlement Signed December 2014 Pooled intellectual property directed to NIPT – Settled all pending infringement disputes – Illumina enforces Patent Pool globally – Shared test fees from licensed laboratories – Sequenom to receive royalty on IVD sales for NIPT kits Sequenom rec
Slide 6: Global Licenses: Partnering for growth
Global Licenses 21 organizations globally granted licenses to the patent pool, including Sequenom Laboratories and Verinata, January 2015 Patent Pool Content Partnering for growth Clarifying the NIPT IP landscape for broader access The patent pool combines critical NIPT patents and patent applicatio
Slide 7: NIPT Collection Pool: Enhancing profitability
NIPT Collection Pool NIPT test fee collection pool Licensees SQNM ILMN SQNM Labs & Verinata Roles and Responsibilities Enhancing profitability Capturing value from the patent pool Illumina and Sequenom collect existing party test fee for the Patent Pool Illumina Responsibilities – License additional
Slide 8: Circulating cell-free DNA Expertise; NIPT leadership
Circulating cell-free DNA Expertise NIPT leadership
Slide 9: Circulating cell-free DNA (ccfDNA)
Circulating cell-free DNA (ccfDNA) Foundational technology / core expertise Cell free fetal DNA in maternal blood – Believed to be from placental and fetally derived cells 1,2,3 Next generation sequencing of ccfDNA allows for accurate identification of fetal chromosomal abnormalities Placental Cells
Slide 10: Traditional prenatal testing
Traditional prenatal testing High risk pregnancies traditionally required invasive procedures High requirement for medical management and genetic counseling 97% of invasive procedures have normal results Invasive testing costly and introduces additional risk
Slide 11: A noninvasive laboratory-developed test (LDT)
A noninvasive laboratory-developed test (LDT) to identify pregnancies at increased risk for fetal chromosomal abnormalities
Slide 12: Our clinical use mirrors criteria in validation study
Our clinical use mirrors criteria in validation study Guidelines established by ACOG and SMFM to perform the test on women at increased risk for fetal chromosomal abnormalities Payors’ medical policies for NIPT is currently for high risk pregnancies MaterniT21 ® PLUS test Indications for use, >375,0
Slide 13: NIPT Market: Large and relatively untapped
NIPT Market: Large and relatively untapped GLOBAL PREGNANCIES >210M births annually US AVERAGE RISK 3.5M births annually US HIGH RISK 750K births annually ¹ $3B+ total market opportunity worldwide 1. Martin JA, et al. Division of Vital Statistics. Births: Final data for 2013. National Vital Statisti
Slide 14: VisibiliT prenatal test
VisibiliT ™ prenatal test Common trisomy information mirrored after content available in standard serum screening Reporting of risk score to complement current medical and genetic counseling practices for average risk Sequenom the first to offer two NIPT testing model Launched internationally in Q4
Slide 15: Sequenom test portfolio: Growing prenatal franchise
First and most comprehensive commercial NIPT for high risk pregnancies First NIPT utilizing common trisomy information mirrored after serum screening content A carrier screen that analyzes the most clinically relevant mutations and variants related to cystic fibrosis (CF) A noninvasive prenatal test
Slide 16: Sequenom continues to innovate NIPT
2011 2012 2014 2013 2015 Sequenom continues to innovate NIPT 1. Expected product launch in 2H 2015 2. Reported as additional findings Trisomy 21 Trisomy 13 Trisomy 18 Sex aneuploidies Enhanced Sequencing Series ² Enhanced Sequencing Series II ² - Additional microdeletions Noninvasive whole genome ka
Slide 17: Noninvasive karyotype
Noninvasive karyotype NIPT portfolio evolution Rapidly accelerate differentiation via our genome wide testing capabilities Noninvasive karyotype – Identifies fetal chromosomal abnormalities currently only seen with invasive procedures Expected launch in 2H 2015
Slide 18: Universal carrier screen opportunity
Universal carrier screen opportunity Rapidly expanding market in prenatal care Screening for genetic disorders as part of preconception care – 6.6M pregnancies in the US annually – Test potential mother and/or father Genetic disorders are among the most common causes of admissions to pediatric hospi
Slide 19: Slide 19
Slide 20: Sequenom enters Oncology
Sequenom enters Oncology Building clinical foundation Engaging key thought leaders from leading institutions: Razelle Kurzrock, MD Murray Professor of Medicine; Chief, Hematology & Oncology; Director, Center for Personalized Cancer Therapy & Clinical Trials, Sr. Deputy Director UCSD Moores Cancer Ce
Slide 21: @@ %
6 @@ %
Slide 22: Oncology program
Oncology program Test type Laboratory-developed test that detects and profiles ctDNA in plasma Target population Advanced cancer patients with solid tumors (stage III-IV) and metastatic patients where (re)-biopsy of tumor tissue is not possible or desired Key activities Clinical advisory board Devel
Slide 23: Financial overview highlights
Highlights Financial overview $ Millions Revenue* $94M*** in cash and investments Reduced cash burn by 66% from $107M** in FY2013 to $37M** in FY2014 Cash burn for Q4 was approximate ly $7M** Annual Cash Burn* $ Millions Note: * Revenue and cash burn exclude Sequenom Bioscience, a discontinued opera
Slide 24: Metrics and 2015 Commentary
Metrics 2015 Commentary 160M covered commercial lives 162K accessioned MaterniT21 ® PLUS tests; 197K total accessioned tests Q4 revenues approximately $37M New Tier CPT code applicable for MaterniT21 ® PLUS NIPT effective January Test fees and royalties are expected to range between $6M to $14M Expe
Slide 25: Corporate Goals 2015
1. Range considers uncertainty in number of Pool Participants, timing of implementing NIPT tests, and the associated timing of test fees and royalties, among other factors. Sequenom expects to have approximately $24M-$27M of non-cash expenses. New Products – Sequenom Laboratories to launch 3 new lab
Slide 26: Contact
CONTACT: CAROLYN D. BEAVER, CFO INVESTORRELATIONS@SEQUENOM.COM WWW.SEQUENOM.COM These laboratory-developed tests were developed and their performance characteristics determined by Sequenom Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although l